The present study is limited by lacking data from other neurodegenerative disorders, which prevents our ability to test the disease specificity of CSF GAP-43 for AD, and whether CSF GAP-43 is associated with other neuropathological biomarkers such as α-synuclein, TDP-43. Here, TARDBP is linked to Alzheimer disease.